Palobiofarma S.L. Announces Positive Top-Line Results from the Phase 2 Trial of Oral PBF-680 in Moderate-to-Severe COPD patients. Primary endpoint was achieved, with PBF-680 demonstrating a statistically significant reduction in blood eosinophil count over 4 weeks Reduction in blood eosinophil...